Charles Schwab’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.37M | Buy |
203,693
+10,976
| +6% | +$73.8K | ﹤0.01% | 2792 |
|
|
2025
Q1 | $1.74M | Sell |
192,717
-4,410
| -2% | -$39.9K | ﹤0.01% | 2657 |
|
|
2024
Q4 | $3.41M | Buy |
197,127
+11,143
| +6% | +$193K | ﹤0.01% | 2514 |
|
|
2024
Q3 | $2.97M | Buy |
185,984
+23,643
| +15% | +$378K | ﹤0.01% | 2588 |
|
|
2024
Q2 | $2.31M | Buy |
162,341
+5,712
| +4% | +$81.4K | ﹤0.01% | 2660 |
|
|
2024
Q1 | $2.22M | Buy |
156,629
+5,271
| +3% | +$74.7K | ﹤0.01% | 2556 |
|
|
2023
Q4 | $2.28M | Sell |
151,358
-3,866
| -2% | -$58.3K | ﹤0.01% | 2571 |
|
|
2023
Q3 | $2.45M | Buy |
155,224
+12,807
| +9% | +$202K | ﹤0.01% | 2541 |
|
|
2023
Q2 | $2.16M | Buy |
142,417
+52,939
| +59% | +$801K | ﹤0.01% | 2522 |
|
|
2023
Q1 | $1.3M | Buy |
89,478
+508
| +0.6% | +$7.37K | ﹤0.01% | 2649 |
|
|
2022
Q4 | $1.2M | Buy |
88,970
+1,111
| +1% | +$15K | ﹤0.01% | 2719 |
|
|
2022
Q3 | $1.39M | Buy |
87,859
+45,077
| +105% | +$711K | ﹤0.01% | 2699 |
|
|
2022
Q2 | $522K | Sell |
42,782
-25,922
| -38% | -$316K | ﹤0.01% | 3059 |
|
|
2022
Q1 | $646K | Buy |
68,704
+4,685
| +7% | +$44.1K | ﹤0.01% | 3020 |
|
|
2021
Q4 | $1.1M | Buy |
+64,019
| New | +$1.1M | ﹤0.01% | 2872 |
|